An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed. Order Research Grade Cagrilintide PekCura Labs A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects Cureus Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Can amylin weight loss drugs compete in a world of GLP 1s? C&EN Global Enterprise Development of a Long Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP 1R Agonists for the Treatment of Obesity Bioconjugate Chemistry